IMAB vs. RENB, RPTX, CTMX, CYBN, SCPH, MCRB, CRVS, GNLX, SYRS, and GOSS
Should you be buying I-Mab stock or one of its competitors? The main competitors of I-Mab include Renovaro (RENB), Repare Therapeutics (RPTX), CytomX Therapeutics (CTMX), Cybin (CYBN), scPharmaceuticals (SCPH), Seres Therapeutics (MCRB), Corvus Pharmaceuticals (CRVS), Genelux (GNLX), Syros Pharmaceuticals (SYRS), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical preparations" industry.
Renovaro (NASDAQ:RENB) and I-Mab (NASDAQ:IMAB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, community ranking, earnings and institutional ownership.
Renovaro's return on equity of 0.00% beat I-Mab's return on equity.
In the previous week, I-Mab had 1 more articles in the media than Renovaro. MarketBeat recorded 6 mentions for I-Mab and 5 mentions for Renovaro. Renovaro's average media sentiment score of 0.72 beat I-Mab's score of 0.61 indicating that I-Mab is being referred to more favorably in the news media.
Renovaro has higher earnings, but lower revenue than I-Mab.
Renovaro has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Comparatively, I-Mab has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.
71.4% of Renovaro shares are owned by institutional investors. Comparatively, 38.4% of I-Mab shares are owned by institutional investors. 21.7% of Renovaro shares are owned by insiders. Comparatively, 22.1% of I-Mab shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
I-Mab has a consensus price target of $12.25, suggesting a potential upside of 602.01%. Given Renovaro's higher probable upside, analysts plainly believe I-Mab is more favorable than Renovaro.
I-Mab received 56 more outperform votes than Renovaro when rated by MarketBeat users.
Summary
I-Mab beats Renovaro on 10 of the 12 factors compared between the two stocks.
Get I-Mab News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
